Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, J. A.
Related Collections
Right arrow MRI
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Multiple sclerosis
NEUROLOGY 2009;72:535-541
© 2009 American Academy of Neurology

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

J. A. Cohen, MD, P. B. Imrey, PhD, P. A. Calabresi, MD, K. R. Edwards, MD, T. Eickenhorst, MD, PhD, W. L. Felton, III, MD, E. Fisher, PhD, R. J. Fox, MD, A. D. Goodman, MD, C. Hara-Cleaver, RN, MSN, G. J. Hutton, MD, B. F. Mandell, MD, PhD, T. F. Scott, MD, H. Zhang, PhD, C. Apperson-Hansen, MStat, G. J. Beck, PhD, P. L. Houghtaling, MS, M. T. Karafa, PhD, M. Stadtler For the ACT Investigators*

From the Cleveland Clinic (J.A.C., P.B.I., E.F., R.J.F., C.H.-C., B.F.M., G.J.B., P.L.H., M.T.K., M.S.), OH; Johns Hopkins University (P.A.C.), Baltimore, MD; MS Center of Southern Vermont (K.R.E.), Bennington; Biogen Idec (T.E., H.Z.), Cambridge, MA; Virginia Commonwealth University Medical Center (W.L.F.), Richmond; University of Rochester (A.D.G.), NY; Baylor College of Medicine (G.J.H.), Houston, TX; Drexel College of Medicine (T.F.S.), Pittsburgh, PA; and Case Western Reserve University (C.A.-H.), Cleveland, OH.

Address correspondence and reprint requests to Dr. Jeffrey A. Cohen, Mellen Center U-10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195 cohenj{at}ccf.org

Objective: To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNβ-1a) combined with methotrexate (MTX), IV methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNβ-1a monotherapy.

Methods: Eligibility criteria included RRMS, Expanded Disability Status Scale score 0–5.5, and ≥1 relapse or gadolinium-enhancing MRI lesion in the prior year on IFNβ-1a monotherapy. Participants continued weekly IFNβ-1a 30 µg IM and were randomized in a 2 x 2 factorial design to adjunctive weekly placebo or MTX 20 mg PO, with or without bimonthly IVMP 1,000 mg/day for 3 days. The primary endpoint was new or enlarged T2 lesion number at month 12 vs baseline. The study was industry-supported, collaboratively designed, and governed by an investigator Steering Committee with independent Advisory and Data Safety Monitoring committees. Study operations, MRI analyses, and aggregated data were managed by an academic coordinating center.

Results: The 313 participants had clinical and MRI characteristics typical of RRMS. Combinations of IFNβ-1a with MTX or IVMP were generally safe and well tolerated. Although trends suggesting modest benefit were seen for some outcomes for IVMP, the results did not demonstrate significant benefit for either adjunctive therapy. The data suggested IVMP reduced anti-IFNβ neutralizing antibody titers.

Conclusions: This trial did not demonstrate benefit of adding low-dose oral methotrexate or every other month IV methylprednisolone to interferon beta-1a in relapsing-remitting multiple sclerosis.

ACT = Avonex Combination Trial; BPF = brain parenchymal fraction; DEXA= dual energy X-ray absorptiometry; EDSS = Expanded Disability Status Scale; GdE = gadolinium-enhancing; IFNβ-1a = interferon beta-1a; IVMP = IV methylprednisolone; MSFC = MS Functional Composite; MTX = methotrexate; N/E = new or enlarged; NAb = neutralizing antibody; OR = odds ratio; RRMS = relapsing-remitting multiple sclerosis; SENTINEL = Safety and Efficacy of Natalizumab in Combination with Interferon β-1a in Patients with Relapsing-Remitting MS.

*The ACT study sites and committee members are listed in appendix e-1 on the Neurology® Web site at www.neurology.org.

Supplemental data at www.neurology.org

Biogen Idec, Inc. funded this study. Pfizer, Inc. provided methylprednisolone.

Preliminary results presented at the annual meeting of the American Academy of Neurology, Boston, MA, May 2007.

Disclosure: Author disclosures are provided at the end of the article.

Received June 3, 2008. Accepted in final form October 16, 2008.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by AAN Enterprises, Inc.